(Q48568691)

12 February 2018

title

Randomized, double-blind, placebo-controlled trial of marimastat in glioblastoma multiforme patients following surgery and irradiation. (English)

1 reference

12 February 2018

1 reference

placebo-controlled trial

1 reference

1 reference

7

1 reference

12 February 2018

author name string

Victor A Levin

1

1 reference

12 February 2018

Surasak Phuphanich

2

1 reference

12 February 2018

W K Alfred Yung

3

1 reference

12 February 2018

Peter A Forsyth

4

1 reference

12 February 2018

Rolando Del Maestro

5

1 reference

12 February 2018

James R Perry

6

1 reference

12 February 2018

Mark Baillet

8

1 reference

12 February 2018

publication date

25 April 2006

1 reference

12 February 2018

Journal of Neuro-Oncology

published in

1 reference

12 February 2018

volume

78

1 reference

12 February 2018

page(s)

295-302

1 reference

12 February 2018

issue

3

1 reference

12 February 2018

https://scigraph.springernature.com/pub.10.1007/s11060-005-9098-5

exact match

0 references

cites work

Criteria for evaluating patients undergoing chemotherapy for malignant brain tumors

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11060-005-9098-5

Minimization: A new method of assigning patients to treatment and control groups

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11060-005-9098-5

Phase III randomized study of postradiotherapy chemotherapy with alpha-difluoromethylornithine-procarbazine, N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosurea, vincristine (DFMO-PCV) versus PCV for glioblastoma multiforme.

21 January 2018

1 reference

12 December 2020

Psychosocial functioning and quality of life in patients with primary brain tumors.

1 reference

12 December 2020

Molecular mechanisms of glioma invasiveness: the role of proteases

1 reference

12 December 2020

Expression and localization of 92 kDa type IV collagenase/gelatinase B (MMP-9) in human gliomas.

1 reference

12 December 2020

Strategies for MMP inhibition in cancer: innovations for the post-trial era.

1 reference

12 December 2020

Expression and localization of 72 kDa type IV collagenase (MMP-2) in human malignant gliomas in vivo.

1 reference

12 December 2020

Response criteria for phase II studies of supratentorial malignant glioma

1 reference

12 December 2020

Angiostatin-converting enzyme activities of human matrilysin (MMP-7) and gelatinase B/type IV collagenase (MMP-9)

1 reference

12 December 2020

Contemporary approaches to the treatment of malignant gliomas with radiation therapy.

1 reference

12 December 2020

METH-1, a human ortholog of ADAMTS-1, and METH-2 are members of a new family of proteins with angio-inhibitory activity

1 reference

12 December 2020

Matrix metalloproteinase inhibitors: a novel class of anticancer agents

1 reference

12 December 2020

Glioblastoma multiforme and anaplastic astrocytoma. Pathologic criteria and prognostic implications

1 reference

12 December 2020

Regulation of angiostatin production by matrix metalloproteinase-2 in a model of concomitant resistance

1 reference

12 December 2020

The Functional Assessment of Cancer Therapy (FACT) scale. Development of a brain subscale and revalidation of the general version (FACT-G) in patients with primary brain tumors.

1 reference

12 December 2020

Matrix Metalloproteinase Inhibitors and Cancer--Trials and Tribulations

1 reference

12 December 2020

1 reference

12 December 2020

Matrix metalloproteinase inhibition: a review of anti-tumour activity

1 reference

12 December 2020

Combined analysis of studies of the effects of the matrix metalloproteinase inhibitor marimastat on serum tumor markers in advanced cancer: selection of a biologically active and tolerable dose for longer-term studies.

1 reference

12 December 2020

Tissue inhibitor of metalloproteinase (TIMP)-2 acts synergistically with synthetic matrix metalloproteinase (MMP) inhibitors but not with TIMP-4 to enhance the (Membrane type 1)-MMP-dependent activation of pro-MMP-2.

1 reference

12 December 2020

Randomised double blind placebo control study of adjuvant treatment with the metalloproteinase inhibitor, Marimastat in patients with inoperable colorectal hepatic metastases: significant survival advantage in patients with musculoskeletal side-effe

1 reference

12 December 2020

A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse

1 reference

12 December 2020

Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme

1 reference

12 December 2020

Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment

1 reference

12 December 2020

10.1007/S11060-005-9098-5

Identifiers

DOI

1 reference

12 February 2018

PubMed ID

16636750

1 reference

12 February 2018